INmune Bio (NASDAQ:INMB) Trading Up 2.6%

INmune Bio, Inc. (NASDAQ:INMB) shares shot up 2.6% during trading on Thursday . The stock traded as high as $6.49 and last traded at $6.39. 65,757 shares traded hands during trading, a decline of 50% from the average session volume of 131,874 shares. The stock had previously closed at $6.23.

Analyst Upgrades and Downgrades

Separately, Scotiabank assumed coverage on INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective for the company.

INmune Bio Price Performance

The company has a market capitalization of $126.41 million, a PE ratio of -3.33 and a beta of 1.86. The stock’s 50 day simple moving average is $7.52 and its 200-day simple moving average is $9.35.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%.

Insider Transactions at INmune Bio

In related news, Director Scott Juda bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The stock was purchased at an average cost of $7.27 per share, for a total transaction of $36,350.00. Following the completion of the acquisition, the director now owns 71,603 shares in the company, valued at approximately $520,553.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 35.20% of the company’s stock.

Institutional Trading of INmune Bio

A number of large investors have recently made changes to their positions in INMB. CVI Holdings LLC purchased a new position in INmune Bio in the second quarter worth approximately $5,260,000. Marshall Wace LLP raised its holdings in shares of INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of INmune Bio during the second quarter worth $121,000. Finally, Westside Investment Management Inc. increased its holdings in INmune Bio by 31.8% in the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after buying an additional 10,950 shares during the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.